Overview

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

Status:
Completed

Trial end date:
2021-01-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin. Participants will administer tirzepatide or placebo along with their previous glucose lowering medications. The study will last approximately 47 weeks and may include about 23 visits.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Gastric Inhibitory Polypeptide
Insulin Glargine
Metformin
Tirzepatide